TACT Board Members

Paul Mitchell (Chair)Australasian Lung Cancer Trials Group (ALTG)
Glenwood GossNational Cancer Institute - Canada (NCIC)
Rebecca HeistAlliance USA
Karen KellySouth West Oncology Group (SWOG)
Bartomeu MassutiSpanish Lung Cancer Group (GECP)
Tony MokAsia representative
Marianne NicolsonNational Cancer Research Institute (NCRI-UK)
Mary O'BrienEuropean Organisation for Research and Treatment of Cancer (EORTC)
Kenneth O'ByrneALTG; European Thoracic Oncology Platform (ETOP)
Nick PavlakisALTG
Suresh RamalingamEastern Cooperative Oncology Group (ECOG)
Rolf StahelSwiss Group for Clinical Cancer Research (SAKK); ETOP
Virginie WesteelFrench Cooperative Thoracic Intergroup (IFCT)
Gerard Zalcman - outgoingFrench Cooperative Thoracic Intergroup (IFCT)

 

 

Paul Mitchell – Board Chair
Olivia Newton-John Cancer and Wellness Centre, Heidelberg VIC, Australia
Dr Paul Mitchell holds the positions of Medical Oncologist at the Olivia Newton-John Cancer and Wellness Centre at Austin Health in Melbourne, Australia, Director of the North-Eastern Melbourne Integrated Cancer Service (Cancer Network) and Associate Professor at the University of Melbourne.  He is immediate past President of the Australasian Lung Cancer Trials Group (ALTG) and has been involved in clinical and laboratory research in thoracic cancer for over 20 years.  Other major contributions to cancer research and clinical care are through appointments to the Lung Cancer Advisory Group of Cancer Australia and previously as non-executive director on the Board of Cancer Trials Australia. He sits on the State Government Cancer Quality and Outcomes Committee, the Program Assessing Committee of the Health Research Council of New Zealand and until recently the Grants Review Committee of the New South Wales Cancer Institute. Dr Mitchell trained in medical oncology in Auckland, New Zealand, followed by two years as Senior Registrar at the Royal Marsden Hospital, UK, before completing a Doctor of Medicine degree based on 3 years work at the Institute of Cancer Research, UK. He moved to Melbourne in 1995.
Glenwood Goss
Ottawa Hospital Cancer Center, Ottawa ON, Canada
Dr. Glenwood Dillon Goss, M.B., B.Ch., FCP(SA), FRCPC graduated at the University of Witwatersrand, Johannesburg, South Africa and completed his post-graduate training at the Royal Marsden Hospital in London, England. He is a Fellow of the Royal College of Physicians and Surgeons of Canada.  Presently, he is the Medical Director of Clinical and Translational Research at The Ottawa Hospital Cancer Centre, the Director of the Lung Cancer Program at The Ottawa Hospital Cancer Centre, Chair, and Professor of Medicine at the University of Ottawa. His principal areas of research relate to investigational new cancer drugs and thoracic oncology. Dr Goss is the Chair of the Thoracic Oncology Site Committee of the Canadian Cancer Trials Group (CCTG). He is a member of the Phase I program at The Ottawa Hospital and a member of the IND Executive Committee, CCTG. He is on the editorial board of a number of peer reviewed journals including the Journal of Clinical Lung Cancer and is a member of the publications committee of International Association for the study of Lung Cancer. He chairs the Clinical Research Executive Committee at the Ottawa Hospital Cancer Centre. His areas of interest are early cancer drug development and thoracic oncology.
Rebecca Heist
Massachusetts General Hospital, Boston MA, USA
Dr. Heist is an Assistant Professor of Medicine at Harvard Medical School. She is a member of the thoracic oncology division at the Massachusetts General Hospital Cancer Center and the Termeer Center for Targeted Therapies.  She serves as an active member of the Respiratory Committee in the Alliance cooperative group. Dr. Heist attended Harvard College and graduated magna cum laude in 1994.  She graduated from Harvard Medical School in 1999 and subsequently completed her internship and medical residency at Massachusetts General Hospital in 2002 and her hematology oncology fellowship in the combined Partners/DFCI program in 2005.  During that time she also earned an MPH in Clinical Effectiveness from the Harvard School of Public Health.  She has been on staff at the Massachusetts General Hospital since 2005. Dr. Heist’s research interests are in the tumor genetics in lung cancer and clinical trials of novel agents in lung cancer. She is Director of the Lung Tumor Bank at MGH and PI of multiple clinical trials in lung cancer.
Karen Kelly
University of California, Davis Medical Center, Sacramento CA, USA
Karen Kelly, MD, is the Associate Director for Clinical Research and holds the Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research at the University of California, Davis Comprehensive Cancer Center and is a Professor of Medicine at the University of California, Davis Medical Center in Sacramento, California. She earned her medical degree from the University of Kansas School of Medicine in 1984 and completed her internal medicine residency in 1987 and oncology fellowship in 1990 at the University of Colorado Health Sciences Center in Denver, Colorado. Dr. Kelly was a member of the faculty at the University of Colorado for 16 years building an academic career in thoracic oncology. Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Her research spans the spectrum of this disease from prevention to treatment. Dr. Kelly has been at the forefront in the development of numerous clinical trials evaluating anticancer agents to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer.   Widely published, Dr. Kelly has authored or co-authored over 190 publications including original papers, reviews and book chaptersShe frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of ASCO, SWOG and the IASLC.
Bartomeu Massuti
Alicante University Hospital, Alicante, Spain
Tony SK Mok
The Chinese University of Hong Kong, Hong Kong
Prof. Tony S. K. Mok BMSc, MD, FRCP(C), FRCP (Edin), FHKCP, FHKAM(Medicine) was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career. He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation. Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is the Past President of the International Association for the Study of Lung Cancer (IASLC), Past Chair of the American Society of Clinical Oncology (ASCO) International Affairs Committee, a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO). He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Editor on Thoracic Oncology for Journal of Clinical Oncology. He has also authored eight books in Chinese and hosted three television series in Hong Kong.
Marianne Nicolson
Aberdeen Royal Infirmary, Aberdeen Scotland, UK
Dr Nicolson is a Consultant Medical Oncologist and Honorary Senior Lecturer at the Aberdeen Royal Infirmary, a post that she has held since 1994. She graduated BSc MBChB from Edinburgh University and after passing MRCP moved to The Institute of Cancer Research and Royal Marsden Hospital in London to study for her MD in drug development (1996) and to complete her CCST in medical oncology.  She became FRCP in 1996. Dr Nicolson runs a busy clinical practice leading systemic treatment for lung cancer, mesothelioma, melanoma, neuroendocrine and unknown primary tumours.  With a major interest in lung cancer treatment, Dr Nicolson chaired the UK National Cancer Research Institute (NCRI) lung cancer clinical study group 2010-2015.  Dr Nicolson is North of Scotland's network clinical lead for cancer research.  She is a chief or local PI for many national/international clinical trials and a member of several trials management groups and IDSMCs. Dr Nicolson is a former member of the Scottish Medicines Consortium, UK Cancer Trials Advisory and Awards Committee (CTAAC), the Quality Implementation Subgroup, SIGN and ESMO lung cancer development groups and Quality Performance Indicator development groups for lung cancer and research. She is a member of the CRUK Clinical Expert Review Committee. Dr Nicolson has published extensively and is regularly invited to lecture nationally and abroad.
Mary O’Brien
Royal Marsden Hospital, Sutton, UK
Mary O’Brien studied medicine at Trinity College Dublin, Ireland. She is currently working as a Medical Oncologist and is Head of the Lung Unit at the Royal Marsden Hospital, Sutton, UK. She specialises in the treatment of all types of lung and breast cancers. In addition, Dr O’Brien was Chair of the Lung Cancer Group of the European Organisation for Research and Treatment of Cancer (EORTC) for 6 years until March 2015. She is principal investigator of the EORTC/ETOP PEARLS trial looking at adjuvant pembrolizumab after lung cancer resection. Dr O’Brien is interested in all aspects of treatment development for small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and mesothelioma, and has participated in recent clinical studies evaluating the potential role of targeted agents, such as cetuximab, erlotinib and immunotherapies in the treatment of NSCLC, oral topotecan in SCLC and chemotherapy for mesothelioma. She also has clinical interests in diagnostic pathways and the supportive care of cancer patients with breathlessness.
Kenneth O’Byrne
Princess Alexandra Hospital, Woolloongabba QLD, Australia
Prof Kenneth O’Byrne is a Consultant Medical Oncologist at Princess Alexandra Hospital and Queensland University of Technology having recently arrived from St James’s Hospital (SJH) and Trinity College, Dublin. He qualified from University College, Dublin (UCD) in 1984, completed his higher professional oncology training at the Churchill Hospital, Oxford 1997 and subsequently worked at the University Hospitals of Leicester NHS Trust and University of Leicester until returning to Dublin in November ’03.  He has a Doctorate Degree in Medicine from UCD and is a Fellow of the Royal College of Physicians, Ireland. He was clinical director of the HOPE directorate at SJH until stepping down on 30th June 2012 after his appointment in Brisbane. Prof O’Byrne is a founder member and president of the British thoracic oncology group (BTOG) and British mesothelioma interest group (BMIG).  He is also a co-founder and board member of the European Thoracic Oncology Platform (ETOP). He is past-chair and current member of the International Association for the Study of Lung Cancer (IASLC) fellowship committee and is a member of the CME committee. He was on the education committee for the IASLC World Conference for Lung Cancer (Sydney 2013) and part of the ESMO chest tumours faculty involved in developing the programs for ESMO meetings in Amsterdam (2013) and Madrid (2014).  Prof O’Byrne was an active member of the Irish Society of Medical Oncology (ISMO) and the Irish Clinical Oncology Research Group (ICORG), chairing the lung cancer disease-specific subgroup. He is a member of the All Ireland Lung Cancer Forum (AILCF), EORTC lung cancer group, American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Prof O'Byrne retains an honorary chair at Trinity College and continues to supervise the thoracic oncology research group in the institute of molecular medicine on the SJH campus focusing on cancer cell survival and drug resistance mechanisms as novel biomarkers and targets for therapy. He and Dr Derek Richard are the directors of the Cancer and Aging Research Program (CARP) at the Translational Research Institute, Brisbane focused on DNA stability. Prof O’Byrne has protected intellectual property for a novel lung cancer diagnostic miRNA signature and Inhibitors of Apoptosis Protein (IAP) targeted novel small molecule SMAC mimetics. Prof O’Byrne is a member of the editorial boards for the Journal of Thoracic Oncology, Lung Cancer, Lung Cancer Management and Chinese Clinical Oncology, has edited 2 text books in thoracic oncology and published over 230 manuscripts in peer-reviewed books and journals http://scholar.google.com/citations?user=cjrLtDQAAAAJ
Nick Pavlakis
Royal North Shore Hospital, St Leonards NSW, Australia
Associate Professor Nick Pavlakis BSc MBBS MMed Clin. Epi. PhD FRACP is Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Associate Professor in the Faculty of Medicine University of Sydney. He has been on staff in the Department of Medical Oncology at Royal North Shore Hospital since 2001 and was Head of Department and Head of the Clinical Trials Unit from 2007-14. He is currently Clinical Services and Trials Director of the Northern Cancer Institute at St Leonards and current Chair of the NET MDT at Royal North Shore Hospital. He has previously served on the Executive of the Medical Oncology Group of Australia (MOGA), the Private Cancer Physicians Group of Australia (PCPA), the Australian Lung Cancer Trials Group (current Chair of Scientific Advisory Committee) and on national and International Advisory boards for colorectal cancer, NETs, RCC, mesothelioma and lung cancers for new cancer drugs. His clinical interests are lung cancers, mesothelioma, and GI cancers. His clinical research focuses on trials in these tumour types and includes new cancer drug development and biomarker studies, especially in the area of anti-angiogenesis drugs. He is involved in translational laboratory research and has co-supervised PhD students examining the EGFR pathway in pancreas cancer and lung cancer. His is currently involved with several laboratory projects examining drug resistance using lung cancer and colorectal cancer models. He has  published over 85 journal manuscripts in each of his interest areas and is a published Cochrane reviewer with new  reviews in progress in lung cancer and colorectal cancer. He has led or is leading ongoing trials with the ALTG and the AGITG, including PI of the AGITG INTEGRATE PII and INTEGRATE II PIII trial and the PII CONTROL NET Study. He has been author and chapter lead in National Clinical Practice guidelines in mesothelioma and lung cancer. Dr Pavlakis has trained and mentored over 22 Advanced Trainees in Medical Oncology since 2002 and lectures annually in the Basic Sciences of Oncology Course, and in registrar training workshops. He has been a faculty member of the bi-annual  Australia & Asia Pacific Clinical Oncology Research Development (ACORD) Workshop. He is on the Senior Examining Panel of the Royal Australasian College of Physicians (RACP). nick.pavlakis@sydney.edu.au
Suresh S. Ramalingam
Winship Cancer Institute, Emory University School of Medicine, Atlanta GA, USA
Suresh Ramalingam is Professor of Hematology and Medical Oncology and Director of the Division of Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, US. Dr Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, US where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA, US. Dr Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He also serves on the Editorial Board of leading cancer journals such as the Journal of Clinical Oncology, Annals of Oncology, Cancer, Clinical Lung Cancer, and Translational Lung Cancer Research. Dr Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is also a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12). Dr Ramalingam serves on several international, national and institutional committees. Dr Ramalingam’s research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. Dr Ramalingam has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. He has published more than 200 original manuscripts, review articles, editorials and book chapters.
Rolf A. Stahel
University Hospital Zürich, Zürich, Switzerland
Rolf A. Stahel, M.D. is head of the Center for Lung and Thoracic Oncology and Senior Staff Physician at the Clinic of Oncology, University Hospital of Zürich as well as Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research and targeted therapy. He was a founding member and the first president of the Swiss Society for Medical Oncology. He served as president of the Swiss Institute for Applied Cancer Research from 1999 to 2005. He is member of the International Association for the Study of Lung Cancer (IASLC), where he served as chair of the fellowship committee and since 2009 is a member of the board of directors. In the European Society for Medical Oncology (ESMO) he served as National Representative from 1998 to 2004 and chaired ESMO Task Force on Guidelines from 1999 to 2005. Since 2003 he is member of the ESMO board of directors and member of the ESMO Executive Committee. From 2006 to 2011 he was the chair of the ESMO Educational Committee, and from 2012 to 2013 he was president-elect of ESMO. Currently he is president of ESMO (2014/2015). Since 2008 he is president of the foundation council of the International Breast Cancer Study Group (IBCSG). Since 2009 he is president of the European Thoracic Oncology Platform (ETOP), a foundation with the aim to bring together European collaborative groups and institutions focusing on research on thoracic malignancies. He is editor in-chief of Lung Cancer and editor of Cancer Treatment Reviews.
Virginie Westeel
University Hospital Besancon, France
Virginie Westeel, M.D., Ph.D. , is Professor of Pulmonology at the University of Franche-Comté, Besançon, France and head of the Thoracic Oncology unit in the University Hospital of Besançon, France. She is a graduate of the University of Franche-Comté, Besançon, France and her specialty is pulmonary medicine. Her clinical and research activities are exclusively dedicated to lung cancer and her research interests include lung cancer therapeutics, follow-up and evidence-based medicine. She is currently the Principal Investigator of the only large multicentre randomized trial on the follow-up after surgery for lung cancer conducted to date, for which she received the Robert Ginsberg Merit Award at the 2015 World Conference on Lung cancer. Her publications mostly include the results of clinical trials in both early-stage and advanced lung cancer. She has taken on the role of Joint Coordinating Editor of the Cochrane Lung Cancer Review Group in 2013. In addition, she led the development of the French guidelines for the staging of lung cancer and she participated in the second ESMO consensus conference in 2014. She has been a member of the scientific committee of the French research group, the Intergroupe Francophone de Cancérologie Thoracique (IFCT), from 2009 to 2013, and she is currently a member of the executive committee of IFCT. She was also a member of the scientific committee of IASLC between 2005 and 2009, of the scientific committee of several WCLC, and she is currently a member of the Communications Committee of IASLC.
Gerard Zalcman – outgoing
University Hospital Center Caen, France
Dr. Gérard Zalcman was initially trained at Paris Medical School and performed his speciality training in pulmonary medicine, medical oncology and molecular biology in Paris 7 University, Saint-Louis Hospital.  He obtained a Master in Pharmacology in 1991 and his M.D. in 1992. He was 1993-1994 French National Insitute for Medical Research (INSERM) visiting scientist at Institut Curie, Paris. He obtained his PhD in Molecular Oncology in 1996. Between 1994 and 1998 he hold an Associate Professor position at Hôpital Saint-Louis, Paris in the Chest Medicine Department and became board-certified in medical oncology in 2000. Between 1998 and 2001, he chaired the Thoracic Oncology Unit in the Medical Oncology Department of Institut Curie, Paris. He became Professor of pulmonary medicine in 2001, and from 2004 he has chaired the Department of Respiratory Diseases at Caen University Hospital. From 2003 to 2009 he was the Secretary of the Scientific Committee of the French Intergroup of Thoracic Cancer research (IFCT), and was elected in 2011 as the Chair of IFCT executive board. Dr. Zalcman is a member of ESMO, ASCO and European Respiratory Society and contributed to the birth of the International Lung Cancer trials group TACT. His main scientific interest is the molecular biology of cell signal transduction, in relation to lung carcinogenesis. He first worked in the field of Rho proteins and their involvement in cytoskeleton control, cell adhesion and motility. He then moved on p53 mutations molecular diagnosis in lung cancer, and contributed to the development of a microarray LDR-based technology for p53 gene mutation detection in small pathological specimens. He described, in a paper published in Nature Medicine, p53 autoantibodies in the sera of heavy smokers as a tool for early diagnosis of lung cancer.  More recently,  he focused his basic research work on the cell consequences of RASSF1A pathway alterations in lung cancer cells leading to the activation of the YAP transcription regulator. In parallel, he has been investigator of more than 50 phase I, II and III clinical trials during the last decade, in the field of lung cancer and mesothelioma. Dr. Zalcman authored or co-authored more than 150 publications including book chapters and articles in peer-reviewed medical and basic science journals, and is the 1st and senor author, respectively, of the two seminal papers from IFCT published in the Lancet journal which respectively reported the role of bevacizumab in mesothelioma treatment and the importance of lung cancer routine molecular assessment. He served as a reviewer for Int. J Cancer, Ann. Oncol.,  ERJ, Lung Cancer, Lancet Oncol., Lancet, PlosOne, JCO and JTO. Since the 1st Sept. 2015, Dr. Zalcman is the Head of the Thoracic Oncology Department of Bichat Hospital, in Paris (Paris-Diderot University).